Pepscope

What Pepscope does

Pepscope is a privately held Dutch biotechnology company founded in 2012 and based in Utrecht, Netherlands. According to its stated mission, the company aims to make protein kinase inhibitors better therapeutics by providing unique insights into their functioning — a niche focus within kinase biology and pharmacology. Its web domain, kinomeactivity.com, signals an emphasis on profiling or measuring kinase activity, suggesting a research-tools, assay, or analytical-services orientation aimed at organizations developing kinase-targeted drugs, though the specific product surface is not documented in the available data.

The company is small, with 1–10 employees, and is led by co-founders Anna Ressa (Chief Executive Officer) and Hans Brouwer. Its only disclosed funding event is a December 2020 round of approximately $5.22 million led by KIKK Capital with participation from the Netherlands Enterprise Agency and OostNL, indicating reliance on a mix of venture and regional economic-development capital. The company website currently resolves to a loading/verification placeholder, and no pricing, customer, product, or revenue disclosures are available in the source material.

As a result, Pepscope's precise go-to-market mechanics — whether it sells assays, data, services, or licensed technology, and to which customer segments — cannot be determined from the input. The company operates in a specialized scientific niche where incumbents tend to monetize through research collaborations, licensing, or services to pharma and academic customers, but this remains an inference rather than an evidenced fact.

Name

Pepscope

Website

https://kinomeactivity.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Pepscope is a small, privately held Dutch biotechnology company founded in 2012 that aims to improve protein kinase inhibitor therapeutics by providing unique insights into kinase functioning, serving kinase drug-discovery researchers from its Utrecht base.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAIALAF

Translational Medicine & Biomarkers

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAGAJAE

Cheminformatics & Molecular Modeling / CADD

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

• Protein kinase inhibitors
• Kinome activity profiling
• Kinase inhibitor research
• Drug discovery services
• Therapeutics development

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Pepscope develops insights and analytical capabilities into protein kinase inhibitors to improve their effectiveness as therapeutics. The company focuses on understanding the functioning of kinase inhibitors, supporting the design and optimization of kinase-targeted drug candidates for pharmaceutical and biotechnology clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Protein Kinase Inhibitor Insights Analytical insights and profiling of protein kinase inhibitors aimed at improving their functioning as therapeutics; delivered to pharmaceutical and biotechnology research clients.
• Kinome Activity Profiling Specialized profiling service that characterizes kinome activity to support kinase-targeted drug discovery and optimization for research clients.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Direct peers

• Reaction Biology: Reaction Biology is a leading CRO specializing in kinase profiling and selectivity panels (e.g., HotSpot, ScanMax). It is a direct peer to Pepscope as both provide kinase activity/selectivity insights to drug discovery sponsors.
• Eurofins DiscoverX: Eurofins DiscoverX (part of Eurofins Pharma Discovery Services) offers kinase activity assays and off-target profiling services. Directly comparable to Pepscope's stated mission of providing insights into kinase inhibitor functioning.

Emerging players

• Kinasity: Kinasity is a specialized start-up focused on kinase inhibitor screening and profiling. Comparable to Pepscope as an emerging niche player in kinase biology with overlapping research-tool positioning.
• Active Motif: Active Motif develops kits, reagents, and services for kinase and cell signaling research. Comparable to Pepscope as a smaller specialist offering research tools and services around kinase/cell signaling pathways.

Broad incumbents

• Charles River Laboratories: Charles River Laboratories is a large CRO offering a broad portfolio including kinase and cell-based assay services for pharma. A broad incumbent whose kinase-related services compete for the same sponsor budgets as Pepscope.
• Thermo Fisher Scientific (Pharma Services): Thermo Fisher's Pharma Services division provides extensive drug discovery and profiling capabilities including kinase assay platforms. Comparable as a large incumbent serving similar pharma R&D customers with overlapping analytical offerings.
• Promega: Promega is an established life sciences tools provider whose kinase activity assays and bioluminescent reagents are used in drug discovery. Overlaps with Pepscope in providing kinase-function readouts to research customers.
• Eurofins Pharma Discovery Services: Eurofins Pharma Discovery Services is the parent-level broad CRO offering that houses DiscoverX and other kinase-related capabilities. A broad incumbent competitor offering comprehensive drug discovery services to similar pharma customers.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/pepscope_kinome

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pepscope